United Kingdom Radiopharmaceutical Market by Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Oncology, Cardiology, Neurology, Others {Respiratory, Musculoskeletal System Diseases, Thyroid, etc.}), By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others {Pharmaceutical Companies, Ambulatory Centers etc.}) and By Region
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Radiopharmaceutical Market by Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Oncology, Cardiology, Neurology, Others {Respiratory, Musculoskeletal System Diseases, Thyroid, etc.}), By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others {Pharmaceutical Companies, Ambulatory Centers etc.}) and By Region
According to a report during the past ten years, the overall number of procedures conducted annually has climbed by 36%. Planar imaging accounts for 73% of all nuclear medicine administrations, with SPECT and PET contributing 165 and 2%, respectively. 7% of all nuclear medicine administrations are for non-imaging diagnostic procedures, and 2% are for therapy.
Increasing Cases of Cancer & Heart Disease
In the United Kingdom, there are about 375,000 new cancer cases per year, around 1,000 cases each day (2016–2018). There are more than 182,000 new cases of cancer in women per year (2016–2018). and there are over 193,000 new cases of cancer diagnosed in men each year (2016–2018) in the United Kingdom.
For Metastatic prostate cancer in bones Radium-223 dichloride (XofigoR) is used. For Thyroid Cancer Sodium Iodide, I-131(HiconR) is used. For Adrenal Gland Lobenguane Iodine-131 (LutatheraR) is used.
Rising Awareness and Adoption of Nuclear Medicine
There are 252 nuclear medicine departments in the United Kingdom and nearly 20 million procedure using radiopharmaceutical carried out annually in the United Kingdom.
there are around 130000 PET-CT scans performed during the year 2019
Nuclear medicine techniques, combined with radiopharmaceuticals, facilitate personalized medicine approaches. By providing functional and molecular information about diseases, nuclear medicine enables tailored treatment plans and improved patient outcomes. The growing awareness about personalized medicine and its benefits drives the demand for nuclear medicine procedures and radiopharmaceuticals.
Developing Centralized Pharmacies to Drive the Market
Most people go to a drugstore at least once every 28 days. In England, prescription drugs were dispensed in more than 1.1 billion times in 2014. This was an increase of 34.5 million over the previous year and an increase of 378.4 million over 2004. Prescribed items had a total net ingredient cost of USD8.9 billion. In England, 89.9% of all things distributed were free of charge.
Centralized pharmacy systems enable better medication reconciliation processes during transitions of care, such as hospital admissions, transfers, and discharges. This ensures that patients' medication lists are accurate, up-to-date, and consistent across different healthcare settings, minimizing the risk of medication discrepancies and adverse events, driving the United Kingdom Radiopharmaceutical Market. Centralized pharmacy systems can facilitate better communication and collaboration among healthcare professionals involved in medication management
Download Free Sample Report
Recent Development
In2021, the $3 billion ultrasound business at GE Healthcare expands beyond diagnostics to include therapeutic and surgical solutions. Significant synergies are anticipated to further boost BK Medical's renowned company as it adds competence in the rapidly expanding advanced surgical visualisation market.
In 2018, Alliance Medical Ltd acquires molecular imaging firms at undisclosed able amount the united company will offer imaging services, radiopharmacies, and cyclotrons, and is anticipated to improve access to imaging agents for clinical trials as well as provide integrated biomarkers.
In 2014, Mallinckrodt acquire Questcor Pharmaceutical in cash and stock valued at approximately USD5.8 billion this is done because it will provide a strong and sustainable platform for future revenue and earnings growth, and provide exceptional value for shareholders of both Mallinckrodt and Questcor
Market Segmentation
The United Kingdom Radiopharmaceutical Market can be segmented by Type, Application, End User, and region. Based on Type, the market can be segmented into Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals. Based on Application, the market can be grouped into Oncology, Cardiology, Neurology, Others. Based on End User, the market can be grouped into Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others.
Market Players
GE Healthcare Ltd, Alliance Medical Ltd, Eckert & Ziegler Radio pharma GmbH, IBA Molecular Ltd, Mallinckrodt Pharmaceuticals Plc, Lantheus Medical Imaging Inc, Jubilant Radiopharma Inc, Sofie Biosciences Inc/United Kingdom. are some of the leading players operating in the United Kingdom Radiopharmaceutical Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Type Application End User |
| Regional scope | Scotland, South-East, London, South-West, Yorkshire & Humberside and East Midlands |
| Key companies profiled | GE Healthcare Ltd, Alliance Medical Ltd, Eckert & Ziegler Radio pharma GmbH, IBA Molecular Ltd, Mallinckrodt Pharmaceuticals Plc, Lantheus Medical Imaging Inc, Jubilant Radiopharma Inc, Sofie Biosciences Inc/United Kingdom. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy